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with responders, mean values of hemoglobin, rEPO dose, ironIntravenous ascorbic acid as an adjuvant therapy for recombi-
metabolism parameters, and E-ZPP showed no significantnant erythropoietin in hemodialysis patients with hyperferriti-
changes in controls (N 5 15) and in non-responders (N 5 19).nemia.
Thirty-seven patients (18 responders and 19 non-responders)Background. Inadequate iron mobilization and defective
were further analyzed by receiver operating characteristiciron utilization may cause recombinant erythropoietin (rEPO)
curves to seek the criteria for prediction of a response to IVAAhyporesponsiveness in hemodialysis (HD) patients with iron
treatment. The results showed that E-ZPP at a cut-off level ofoverload. We have demonstrated that intravenous ascorbic acid
more than 105 mmol/mol heme and TS at a level of less than(IVAA), but not intravenous iron medication, can effectively
25% were more specific to confirm the status of functional ironcircumvent the functional iron-deficient erythropoiesis associ-
deficiency in iron-overloaded patients. The two criterion valuesated with iron overload in HD patients. However, it is uncertain
whether all HD patients with hyperferritinemia will consis- had the highest accuracy to predict a response to treatment.
tently respond to IVAA and which index may indicate func- Conclusions. Functional iron-deficient erythropoiesis plays
tional iron deficiency in the special entity. Therefore, a prospec- a role in rEPO-hyporesponsive anemia in HD patients with
tive study was conducted to establish the guidelines for IVAA hyperferritinemia. IVAA may be an adjuvant therapy for rEPO
adjuvant therapy. in these patients, and E-ZPP of more than 105 mmol/mol heme
Methods. Sixty-five HD patients with serum ferritin levels and TS of less than 25% should be used to guide the IVAA
of more than 500 mg/liter were recruited and divided into the treatment.
control (N 5 19) and IVAA (N 5 46) groups. IVAA patients
with a hematocrit (Hct) of less than 30% received 300 mg of
ascorbic acid three times per week for eight weeks. Controls
In the era of recombinant erythropoietin (rEPO), hy-had a Hct of more than 30% and did not receive the adjuvant
therapy. Red blood cell and reticulocyte counts, iron metabo- perferritinemia in dialysis patients is always attributed
lism indices, erythrocyte zinc protoporphyrin (E-ZPP), and the to previous multiple transfusions and overtreatment with
concentrations of plasma ascorbate and oxalate were examined intravenous iron if the state of inflammation, liver dis-
before and following the therapy.
ease, or malignancy is excluded. The ferritin level toResults. Thirteen patients (four controls and nine IVAA
indicate hyperferritinemia for hemodialysis (HD) pa-patients) withdrew by the end of the study. Eighteen patients
had a dramatic response to IVAA with a significant increase tients is suggested to be over 500 to 1000 mg/liter [1–4].
in their hemoglobin and reticulocyte index and a concomitant Cellular iron overload plays an important role in a num-
24% reduction in rEPO dose after eight weeks. This paralleled ber of pathological states. It produces a variety of delete-
a significant rise in serum iron and transferrin saturation (TS)
rious effects, including hemosiderosis [5, 6], hepatic andand a fall in E-ZPP and serum ferritin (baselines vs. 8 weeks,
cardiac dysfunction [7], and cardiovascular and infec-serum iron 68 6 37 vs. 124 6 64 mg/dl, TS 27 6 10 vs. 48 6
19%, E-ZPP 123 6 44 vs. 70 6 13 mmol/mol heme, and serum tious morbidity [8]. It may also sometimes cause the
ferritin 816 6 435 vs. 587 6 323 mg/liter, P , 0.05). Compared relative resistance to rEPO [9]. The mechanism remains
obscure, but inadequate iron mobilization and defective
iron utilization are the possible causes [5, 9, 10]. ThisKey words: iron overload, erythropoiesis, anemia, transferrin satura-
tion, dialysis, zinc protoporphyrin. condition mimics functional iron deficiency when rEPO
accelerates erythropoiesis to an extent that the body’sReceived for publication October 28, 1998
iron demand exceeds the capacity of tissue iron releaseand in revised form December 29, 1998
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receiving rEPO treatment. However, the promising ef- METHODS
fect of intravenous iron medication in patients with iron Patients and study design
overload was not observed in our previous study [14] or
From 1 November 1997 to 30 April 1998, a prospectivethe one by Goch et al [15]. The results were also found
study was conducted at the Veterans General Hospitalin scorbutic animals [16]. Supplementation of iron did
(Taipei, Taiwan) to recruit 65 HD patients (29 men andnot improve the anemia, but increased the deposition of
36 women) with serum ferritin values of more than 500hemosiderin in spleen, small intestine, and bone marrow.
mg/liter. Hyperferritinemia was related to previous mul-Because tissue iron deposition is sufficient enough to
tiple blood transfusions or overtreatment with intrave-cause organ damage, the risks related to iron overload
do not justify intravenous iron therapy for patients with nous iron. Inclusion criteria were time on HD for six
hyperferritinemia. Consequently, an adjuvant therapy to months or more, duration of rEPO treatment for six
combat the functional iron deficiency related to iron months or more, and serum ferritin and hematocrit (Hct)
overload is urgently needed. values that were stable for three consecutive months. In
Bothwell et al reported that Bantu subjects with scurvy the preceding three months, none of the patients had
had excessive iron deposits in tissues, which modified the received iron supplements or blood transfusions. Pa-
metabolism of ascorbic acid [17]. It is still controversial tients were excluded if any of the following events oc-
as to whether normal plasma ascorbate values reflect a curred during the study: bleeding, blood transfusions,
normal vitamin C status in uremics. Tissue concentration
hemolysis, acute liver diseases, and infections. Most pa-of vitamin C is often decreased in patients with iron
tients routinely received multivitamin supplementation,overload, perhaps because of increased vitamin oxida-
but the supplements did not include vitamin C in ourtion catalyzed by iron. Moreover, subclinical vitamin C
center. In the dietary survey data for estimating nutrientdeficiency is frequently encountered in HD patients ow-
intake [30], vitamin C content of the diet varied betweening to its removal during dialysis and insufficient dietary
40 and 302 mg/day before the start of the investigation.intake [18–20]. Thus, systemic supplementation of ascor-
Patients were dialyzed for 4.0 to 4.5 hours three timesbic acid is recommended. Gastaldello et al [21] and Tarng
and Huang [14] had demonstrated that intravenous per week using cellulose acetate hollow-fiber (FB 130T,
ascorbic acid (IVAA) treatment effectively improves the Niprot; Nissho, Japan), blood flow of 275 to 300 ml/min,
resistant anemia associated with functional iron defi- and dialysate flow of 500 ml/min. The study was approved
ciency in HD patients with iron overload. A number by the local medical ethics committee, and informed
of investigations suggested that ascorbic acid might be consent was obtained from each of the patients.
involved in several phases of iron transport [16, 17, 22, Patients were stratified into IVAA and control groups
23]. Ascorbic acid, a reducing agent, is able to release according to Hct values. Basal Hct values were less than
iron from ferritin and mobilize iron from the reticuloen- 30% in IVAA group and were more than 30% in con-
dothelial system to transferrin [14, 21]. This leads to an
trols. IVAA patients received ascorbic acid, 300 mg each,increase of iron availability.
administered intravenously for three minutes postdial-However, the role of ascorbic acid in the enzymatic
ysis three times per week. The study period includedincorporation of iron into protoporphyrin for heme syn-
eight weeks of treatment and four weeks of post-treat-thesis [22, 23] has never been studied in this field. Zinc
ment follow-up. Based on the study by Gastaldello etprotoporphyrin (ZPP) is a by-product of heme biosyn-
al, erythropoiesis was not further enhanced by IVAAthesis. Erythrocyte ZPP (E-ZPP) levels will increase if
treatment in patients with good response to rEPO [21].the enzymatic iron incorporation for heme synthesis is
insufficient or suppressed. Accordingly, an increased Thus, controls did not receive the adjuvant therapy in our
E-ZPP value indicates functional iron deficiency [24–27]. study. rEPO (Eprext; Cilag, Schaffhausen, Switzerland)
In this study, we therefore applied the conventional iron was administered subcutaneously twice or three times
metabolism indices and E-ZPP to elucidate the mecha- per week, and the dose was maintained during the initial
nism of action of IVAA. On the other hand, it is uncer- two weeks. After two weeks, the dose was decreased by
tain whether all patients with hyperferritinemia and a 3 3 15 U/kg/week if the Hct increased to more than
suboptimal response to rEPO will respond to the IVAA 31%. The dose was titrated biweekly to maintain a target
treatment. For the sake of cost-effectiveness, we ana-
Hct value of 30 to 31%. Response to IVAA treatmentlyzed the markers to set up the criteria for functional
was defined as an increase in Hct of 3% or more or airon deficiency in patients with hyperferritinemia and
decreased in rEPO dose of more than 25% over theto guide the IVAA as an adjuvant therapy for rEPO.
baseline value at study completion. In subjects who failedSecondary oxalosis is a potential risk in HD patients
to show a positive response to IVAA for four weeks,treated with excessive ascorbic acid [28, 29]. It is manda-
rEPO dose was further increased by 3 3 15 U/kg/weektory to monitor the plasma oxalate concentration to avoid
the inadvertent side effect during the IVAA treatment. biweekly if Hct declined.
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Laboratory measurements 0.5 ml of MPA-treated plasma. After thoroughly and
slowly mixing, the mixture was allowed to stand for 30Blood was drawn predialysis after an overnight fast.
minutes at room temperature and then centrifuged forHematocrit and hemoglobin (Hb) levels, and the reticu-
15 minutes at 1000 3 g. The blue-colored supernatantlocyte index were checked biweekly and were determined
was transferred to another test tube, and absorbance atwith a Coulter counter. Reticulocyte was measured by
700 nm was read against a blank constituted with distilledan automated flow cytometer, and a reticulocyte index
water. For every set, a standard (1 mg/dl ascorbic acidwas calculated using the following formula: observed
with 0.5% oxalic acid) and a blank were run in parallelreticulocyte count (%) 3 (patient’s Hct 4 45%). E-ZPP
throughout the procedure.and iron metabolism indices including serum iron, total
Plasma oxalate was measured by the method describediron-binding capacity (TIBC), and serum ferritin were
by Petrarulo et al [33]. Briefly, 1 ml of 10-fold dilutedmeasured before, as well as two, four, and eight weeks
plasma was added with 100 ml of 1.57 mol/liter sulfosali-following therapy. ZPP was determined by a fluorometer
cylic acid solution for deproteinization. After centrifuga-described by Schifman and Finley [31]. In brief, 2 ml
tion for 10 minutes at 5000 3 g and 48C, 700 ml of theof blood in an ethylenediaminetetraacetic acid (EDTA)
supernatant was mixed with 700 ml of buffered charcoaltube was centrifuged for five minutes at 500 3 g within
suspension (100 mg of charcoal in 10 ml of phosphate/10 minutes of collection. The supernatant was removed,
EDTA buffer, pH 7.3). The 750 ml of charcoal-treatedand erythrocytes were washed twice with an equal vol-
sample combined with 600 ml of 25 mmol/liter 3-methyl-ume of 0.9% saline. A microscope slide, on which 25 ml
2-benzothiazolione hydrazone hydrochloride/8.2 mmol/of washed erythrocytes were placed, was put into a hema-
liter 3-dimethylaminobenzoic acid, and 150 ml of 1000tofluorometer (Aviv Biomedical Inc., Lakewood, NJ,
U/ml peroxidase were incubated for 30 minutes at roomUSA) for the measurement of ZPP. Calibration with
temperature. The mixture (700 ml) was added with 140 mlstandard control was performed before testing. Serum
of 3.3 U/ml oxalate oxidase and incubated for 60 minutesiron was measured by a colorimetric method (Hitachi
at room temperature. Absorbance at 590 nm was read736-60 autoanalyzer; Naka, Japan), TIBC by the TIBC
with a spectrophotometer (Hitachi U-3300; Naka, Ja-
Microtest (Daiichi, Tokyo, Japan), and ferritin by a ra-
pan). Blanks were prepared similarly by substituting wa-
dioimmunoassay (Incstar, Stillwater, MN, USA). Trans-
ter for oxalate oxidase.
ferrin saturation (TS) was equal to divide serum iron by
TIBC 3 100. Statistical analysis
To investigate the factors pertaining to rEPO respon- Statistical analysis was performed using the computer
siveness, serum aluminum, intact parathyroid hormone software Statistical Package of Social Science (SPSS 7.5,
(PTH), inflammatory indices (C reactive protein and 1996; SPSS Inc., Chicago, IL, USA). Data were ex-
fibrinogen), and hemolytic indices (haptoglobin and re- pressed as mean values 6 sd. Analysis of variance fol-
ticulocyte index) were checked at the inception of study. lowed by pair-wise multiple comparison was used for
Serum aluminum was determined in duplicate by a comparison of more than two groups. Pearson’s chi-
graphite furnace atomic absorption spectrophotometer square test was used for frequency measures. A within-
(GBC-906 spectrophotometer; Dandenong, Australia). group comparison among post-treatment values and
The detection limit was 0.5 mg/liter, and the coefficient baselines was analyzed by analysis of variance for re-
of variation was lower than 4%. Serum intact PTH was peated measures, followed by pair-wise multiple compar-
measured by a radioimmunoassay (Incstar), C reactive ison. Receiver operating characteristic analysis was per-
protein by a rate nephrelometry (Beckman, Galway, Ire- formed to calculate the cut-off values, sensitivity,
land), fibrinogen by the clotting method (Diagnostics specificity, and positive and negative predictive values.
Stago, Asnieres-Sur-Seine, France), and haptoglobin by A P value of less than 0.05 was considered statistically
radial immunodiffusion (Behring Diagnostics, Marburg, significant.
Germany).
The concentrations of plasma ascorbate and oxalate
RESULTSwere determined in duplicate before, as well as four
and eight weeks into the study. Plasma ascorbate was Thirteen patients (4 in controls and 9 in the IVAA
measured by a method described by Kyaw [32]. An ali- group) had withdrawn by the end of study because of
quot of 0.5 ml plasma was mixed with 0.5 ml of 100 g/ gastrointestinal bleeding (N 5 5), pneumonia (N 5 2),
liter metaphosphoric acid (MPA) and stored at 2708C uremic pericarditis (N 5 1), cervical carcinoma (N 5 1),
until measurement. Color reagent was prepared by mix- and discontinuation of therapy (N 5 4). Finally, a total
ing 0.3 mmol/liter sodium tungstate, 1.2 mmol/liter so- of 52 patients completed the study: 15 in controls, 18 in
dium hydrogen phosphate, and 18 mol/liter sulfuric acid. the IVAA responders, and 19 in the non-responders
(Table 1). The three groups were similar with regard toOne milliliter of color reagent was slowly added into
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Table 1. Characteristics of the hemodialysis patients recruited in this study
IVAA IVAA
Controls responders non-responders
Demographic characteristics
Number 15 18 19
Age years 57617 59 613 52 610
Sex male/female 7/8 6/12 7/12
Duration of hemodialysis months 47664 62 652 37 632
Time on rEPO treatment months 1869 28 620 23 616
Causes of end-stage renal disease
Chronic glomerulonephritis 6 8 4
Chronic interstitial nephritis 4 1 5
Hypertensive nephrosclerosis 1 2 2
Diabetic nephropathy 4 4 4
Lupus nephritis 0 2 4
Unknown 0 1 0
Baseline data
Hemoglobin g/dl 10.860.8 8.960.7a 8.560.8a
Hematocrit % 31.562.1 26.562.1a 25.062.6a
MCV f l 92.065.8 90.9 65.7 92.3 64.9
rEPO dose U/kg/week 71623 98629a 100620a
Serum ferritin lg/liter 9116557 816 6435 977 6710
Serum iron lg/dl 92646 68 637 87 654
Transferrin saturation % 45620 27 610a,b 37616
Erythrocyte ZPP lmol/mol heme 73614 135643a,b 91618
Serum aluminium lg/liter 32611 26 610 28 612
Intact PTH pg/ml 1526181 77 664 107696
C-reactive protein mg/dl 0.861.5 0.4 60.5 0.3 60.3
Fibrinogen mg/dl 3636101 356 676 368 670
Reticulocyte index % 1.260.3 1.4 60.6 1.9 60.5
Haptoglobin mg/dl 2036121 161 678 170 652
Abbreviations are: IVAA, intravenous ascorbic acid; rEPO, recombinant erythropoietin; MCV, mean corpuscular volume; ZPP, zinc protoporphyrin; PTH,
parathyroid hormone.
a P , 0.05, responders or nonresponders vs. controls
b P , 0.05, responders vs. nonresponders
age, sex, duration of HD, time on rEPO treatment, and U/kg/week) and at eight weeks (75 6 44 U/kg/week)
were significantly reduced as compared with baselinecauses of chronic renal failure. Hb and Hct values were
significantly lower, and the rEPO dose was markedly values (P , 0.05) in responders. On the contrary, the
rEPO dose of non-responders modestly increased fromhigher in both IVAA responders and non-responders as
compared to controls. Serum ferritin, serum iron, and 100 6 20 to 123 6 69 U/kg/week at treatment completion,
and it became significantly higher than that in respondersother factors pertaining to rEPO responsiveness showed
no differences among the three groups. None of the at eight weeks (Fig. 1B). The overall rEPO dose had a
24% reduction in responders and a 23% increment inpatients in the treatment groups received any active vita-
min D analogue. Impressively, TS was significantly non-responders. Sixty-seven percent of responders could
reduce rEPO dose at treatment completion, whereaslower, and E-ZPP was significantly higher in IVAA re-
sponders than those in the others. 29% of non-responders needed to increase rEPO dose.
In control subjects, the rEPO dose remained stable for
Effect of intravenous ascorbic acid therapy eight weeks. Mean values of Hb (10.8 6 0.8 g/dl at base-
line vs. 10.4 6 1.0 g/dl at 8 weeks), Hct (31.5 6 2.1%Hemoglobin and Hct values significantly increased at
two weeks and all subsequent weeks following ascorbate vs. 31.1 6 2.4%), and reticulocyte index (1.2 6 0.3% vs.
1.4 6 0.3%) in controls kept steady throughout the studytreatment in the IVAA responders (Fig. 1A). Mean Hb,
Hct, and reticulocyte index increased from 8.8 6 0.5 g/dl (Fig. 1).
at baseline to 10.7 6 0.9 g/dl at eight weeks (P , 0.001)
Post-treatment follow-up and monitoring plasmafrom 26.4 6 1.8 to 31.6 6 2.8% (P , 0.001) and from
ascorbate and oxalate1.4 6 0.6 to 2.9 6 0.8% (P , 0.05), respectively. Non-
responders, however, showed no improvement in mean Hemoglobin values significantly decreased from 10.7 6
0.9 to 9.9 6 0.7 g/dl (Fig. 2), and the rEPO dose increasedvalues of Hb (8.5 6 0.8 g/dl at baseline vs. 8.2 6 1.0
g/dl at 8 weeks), Hct (25.0 6 2.6 vs. 24.0 6 3.0%), and from 75 6 44 to 94 6 47 U/kg/week in responders four
weeks after stopping IVAA treatment. However, therereticulocyte index (1.9 6 0.5 vs. 2.1 6 0.8%).
Therapeutic doses of rEPO at four weeks (84 6 34 were no significant changes of Hb values (8.2 6 1.0 g/dl
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compared with baseline values. Serum iron markedly
increased at two weeks and all subsequent weeks, and
this paralleled a significant increase in TS (Fig. 3). The
four parameters in non-responders and controls had no
significant changes during the treatment period. At treat-
ment completion, serum ferritin became significantly
lower and serum iron higher in responders as compared
with non-responders. TS and E-ZPP of the patients in
the three groups were similar at eight weeks.
Indices to predict who will respond to the intravenous
ascorbic acid treatment
To identify the indices to predict a response to the
IVAA treatment, 18 responders plus 19 non-responders
were further analyzed by receiver operating characteris-
tic curves (Table 3). The results showed that E-ZPP and
TS were more specific to all the tests at the cut-off values
of more than 105 mmol/mol heme and less than 25%,
respectively (Fig. 4). The criterion values indicated the
status of functional iron deficiency with the highest accu-
racy (minimal false negative and false positive results) in
iron-overloaded patients. The positive predictive value
increased from 86 to 87 to 100%, and the negative pre-
dictive value was 70% when the two markers at the
corresponding cut-off values were combined to use.
DISCUSSION
A deficiency of water-soluble vitamin C has been re-
ported in HD patients owing to inadequate dietary in-
Fig. 1. Changes of hemoglobin concentration (A ) and recombinant take, loss through the dialyzer, and uremia-associatedhuman erythropoietin doses (B) following intravenous ascorbic acid
metabolic derangement [18–20]. Because it increases thetreatment. Symbols are: (n, ) controls; (d, j) responders; (s, h)
non-responders. Brackets indicate sd. *P , 0.05 vs. baselines; †P , need of vitamin C for HD patients, a supplementation
0.05 vs. controls; and #P , 0.05 vs. responders. of ascorbic acid is essential. A daily dose of 100 to 200
mg is recommended in some reports [18–20, 34], but the
prescription of vitamin C in different dialysis facilities
varies between 55 and 1000 mg daily [34–36]. Excessiveat 8 weeks vs. 7.9 6 0.7 g/dl at 12 weeks) and rEPO dose
vitamin C treatment may worsen uremic-related ox-(123 6 69 vs. 121 6 65 U/kg/week) in non-responders.
alosis. Hence, supplementation not exceeding 150 mg/The body weight (controls, responders, and non-respond-
day (1050 mg weekly) is still considered a safe dose [29].ers at 52 6 9, 57 6 16, 54 6 10 kg, respectively) and
In this study, the dose of IVAA (900 mg weekly) is lessvitamin C content of daily diet (controls, responders,
than the recommended regimen. Following a short-termand non-responders at 140 6 92, 146 6 83, and 136 6
treatment, plasma oxalate concentrations only modestly89 mg/day, respectively) were comparable among the
increased as compared with baselines (P . 0.05).three groups. The concentrations of basal plasma ascor-
Ascorbic acid was administered intravenously in thisbate and plasma oxalate were also similar in the three
study. It has the advantage of the oral route. The bio-groups (Table 2). Following eight weeks of treatment,
availability is variable in HD patients receiving oralthe concentrations of plasma ascorbate significantly in-
ascorbic acid. Furthermore, gastrointestinal upset (espe-creased in both responders and non-responders (P ,
cially at a large dose) and noncompliance may reduce0.01), but plasma oxalate modestly increased over base-
the efficacy of oral treatment.lines without reaching statistical significance (P . 0.05).
The three groups of patients in our study were equiva-
Alterations in iron metabolism indices and erythrocyte lent with respect to the basal concentrations of plasma
zinc protoporphyrin ascorbate. However, it is unclear whether normal plasma
values reflect a normal vitamin C status. The metabolismIn the IVAA responders, the mean values of serum
ferritin and E-ZPP at eight weeks significantly decreased of ascorbic acid and iron is believed to be interrelated.
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Fig. 2. Post-treatment follow-up of hemoglo-
bin concentration in responders (A ) and non-
responders (B ) after cessation of intravenous
ascorbic acid. Symbols are: (d) responders;
(s) non-responders. Squares indicate mean
values, and brackets indicate sd. *P , 0.05
vs. at eight weeks.
Table 2. Alterations of plasma ascorbate and oxalate concentrations [11–13]. The responders had an initially lower TS despite
during 8 weeks of study the fact that they had enlarged iron stores. The prompt
Controls Responders Nonresponders rise in plasma iron and TS occurred when ascorbic acid
Parameters (N515) (N518) (N519) was administered. It seemed to be due to an increased
Plasma ascorbate mg/dl release of iron into the plasma, presumably from reticu-
Week 0 0.98 60.23 1.27 60.27 1.13 60.20 loendothelial stores. The utilization of storage iron con-Week 4 1.07 60.24 2.9661.68a,b 3.1460.87a,b
tinued till the end of treatment, as indicated by a slowWeek 8 1.10 60.31 2.7060.45a,b 2.5660.49a,b
Plasma oxalate lmol/liter and significant decline in serum ferritin values. The fact
Week 0 47.0 610.6 49.3 615.5 46.4 610.1 suggests that ascorbic acid acts as a mediator to facilitateWeek 4 46.7 69.9 56.9 611.0 55.1 612.2
iron release from inert iron depots and delivery to hema-Week 8 49.1 616.7 60.1 613.2 58.6 614.3
topoietic tissues.a P , 0.05 vs. controls by between-group comparison
b P , 0.05 vs. Week 0 by within-group comparison Goldberg et al confirmed that protoporphyrin was an
intermediate in heme biosynthesis and that the mecha-
nism of iron-incorporation for heme synthesis was enzy-
matic [22]. Goldberg further indicated that ascorbic acid
It has been suggested that patients with hemosiderosis plays a role in keeping up Hb iron in the reduced state
living on a borderline diet may develop clinical scurvy and potentiates the enzymatic iron incorporation into
as a result of irreversible oxidation of ascorbate by the protoporphyrin [23]. ZPP is a by-product of heme syn-
excessive deposits of ferric iron [37]. Anemia improved thesis. Its level in the erythrocyte may increase if the
after the administration of IVAA and relapsed after enzymatic incorporation of iron into protoporphyrin is
stopping treatment in the 18 responders. It might be suppressed or insufficient. Thus, E-ZPP was recently re-
possible that tissue ascorbate depleted severely in the ported as a marker of endogenous iron-deficient erythro-
iron-overloaded responders. Although there is no con- poiesis in renal as well as nonrenal anemia [24–27]. In
crete evidence to support this contention, two observa- this study, basal E-ZPP levels in responders substantially
tions are at least compatible with it [14, 21]. elevated as compared with the other two groups and
In the scorbutic animals [16] and the Bantu with scurvy significantly decreased after eight weeks of the IVAA
[17], defective iron utilization related to ascorbate defi- treatment. Our results corroborate the observations [22–
ciency was indicated by several observations, including 27]. The dual effects of IVAA treatment, an increase of
normocytic and normochromic anemia, diminished iron mobilization, and an improvement of heme biosyn-
plasma iron, and increased free erythrocyte protopor- thesis enhance the erythropoietic response to rEPO and
result in a Hb rise.phyrin. TS is one of the markers for iron availability
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Fig. 3. Effect of intravenous ascorbic acid on
serum ferritin (A ), serum iron (B ), transferrin
saturation (C ), and erythrocyte zinc protopor-
phyrin (D). Symbols are: (n) controls; (d)
responders; (s) non-responders. Brackets in-
dicate sd. *P , 0.05 vs. baselines; †P , 0.05;
and ††P , 0.05 vs. responders.
Table 3. Predictive values of chosen cutoff pointsa for iron metabolism indices in 37 hemodialysis patients with hyperferritinemia and
hyporesponsiveness to recombinant erythropoietin
Sensitivity % Specificity % Positive Negative
Criteria 95% C.I. predictive value %
Erythrocyte ZPP.105 mmol/mol heme 72 90 87 77
[47, 90] [67, 98]
Transferrin saturation ,25% 67 90 86 74
[41, 87] [67, 98]
Erythrocyte ZPP.105 mmol/mol heme
and transferrin saturation ,25% 56 100 100 70
[32, 82] [92, 100]
Serum iron ,50 mg/dl 50 84 75 64
[26, 74] [60, 96]
Serum ferritin ,760 mg/liter 67 58 60 65
[41, 87] [34, 80]
TIBC .210 mg/dl 44 84 73 62
[22, 69] [60, 96]
MCV ,90 fl 56 68 63 62
[31, 78] [44, 87]
Abbreviations are: C.I., confidence interval; ZPP, zinc protoporphyrin; TIBC, total iron binding capacity; MCV, mean corpuscular volume.
a Cutoff values for variables were chosen using receiver operating characteristic curves
No elevation of Hb was noted in non-responders after months or more. Gastaldello et al reported that there
was no significant change in Hct or TS in seven controlchallenge with IVAA. The non-responders significantly
had higher basal TS and lower E-ZPP as compared with patients without resistance to rEPO following IVAA
treatment [21]. Accordingly, we believe that it is illogicalresponders. It implied that the iron availability and utili-
zation are sufficient in this group. Because individual to administer IVAA medication to all our patients. The
use of IVAA can be considered as an adjuvant therapyresponse to rEPO is variable in dialysis or predialysis
patients [38, 39], the increase of rEPO dose by an escala- for rEPO if hyporesponsive anemia related to functional
iron deficiency occurred in HD patients with hyperferriti-tion manner should be considered while other factors
pertaining to rEPO resistance (Table 1) do not exist. nemia. With the consideration of cost-effectiveness, we
further analyzed the basal iron metabolism indices andControls in this study had an optimal response to rEPO
and maintained the stable erythropoiesis for three E-ZPP to establish the therapeutic guidelines for the
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nous iron for six months [46]. On the contrary, a high
E-ZPP level (more than 105 mmol/mol heme) not only
represents a marker of endogenous iron availability but
also a predictor for a response to IVAA in our study.
In this study, anemia was improved after the adminis-
tration of IVAA, and serum ferritin declined simultane-
ously at the end of the study. IVAA may also reduce
the magnitude of iron overload in uremic patients. Con-
fronted with the potential hazards of iron overload,
IVAA provides an additional benefit for iron-over-
loaded HD patients because of its property mimicking
iron-chelation agents. Ascorbic acid combined with des-
ferrioxamine (DFO) results in very efficient removal of
iron in nonuremic patients with iron overload [47, 48].
It has been demonstrated that DFO enhances burst-
forming unit-erythroid proliferation [49] and also im-Fig. 4. Scatter plots of transferrin saturation (A ) and erythrocyte zinc
proves anemia in iron-overload HD patients [15, 50].protoporphyrin (B ) in responders (N 5 18) and non-responders (N 5
19). The cut-off values, expressed by the dotted lines, for transferrin Therefore, the long-term IVAA alone or combined with
saturation and erythrocyte zinc protoporphyrin are 25% and 105 mmol/ DFO appears to be promising in HD patients with iron
mol heme, respectively.
overload. Certain laboratory and clinical observations
have raised concern about the safety of using ascorbic
acid in patients with severe iron overload. Some cardiac
deaths [47, 48] and deterioration of cardiac function [51]IVAA treatment. Receiver operating characteristic
curves were used to calculate the cut-off value of each have been reported in thalassemic children receiving
index that could maximize the sensitivity, specificity, and DFO and ascorbic acid. Ascorbic acid promotes electron
predictive values. We found that E-ZPP at a cut-off value exchange and, in vitro, can be shown to enhance the
of more than 105 mmol/mol heme and TS of less than cytotoxicity of iron. However, similar findings were not
25% were more specific to the status of functional iron- observed in nonthalassemic adults with transfusional
deficient erythropoiesis in patients with iron overload. iron overload during chelation therapy [52], and vitamin
E-ZPP and TS at the cut-off values had the superior C exhibits antioxidant activity in iron-overloaded human
positive predict values for predicting a response to IVAA plasma [53]. Despite that untoward cardiac events associ-
treatment. If both tests were abnormal, the positive pre- ated with ascorbic acid may not be a potential problem
dictive value increased to 100%. in uremic patients, it is mandatory to evaluate and follow
Transferrin saturation indicates a balance between up the cardiac function, particularly when vitamin C is
supply and demand of plasma iron. TS has wide fluctua- being administered intravenously on a weekly basis [51,
tions because of a diurnal variation in serum iron and 52]. Because many patients with iron overload have re-
transferrin affected by the nutritional status. Neverthe- ceived the drug without any apparent harm, data from
less, a series of follow-up is crucial if TS is to act as an large-scale, prospective, and controlled trials are needed
index of functional iron deficiency [40]. A TS of less than to determine the safety and efficacy of a long-term IVAA
16 to 20% is suggestive of functional iron deficiency in HD patients with iron overload.
[41–43]. However, it may lead to underdiagnosis in most
HD patients when current guidelines for TS are used. ACKNOWLEDGMENTS
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